{
  "symbol": "LLY",
  "year": 2023,
  "Period": "Q3",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": -0.2732,
    "outlook_sentiment": 0.1193,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.151
  },
  "top_positive": [
    {
      "sent": "22 Fair Value of Risk-Management Instruments The following table summarizes certain fair value information at March\u00a031, 2023 and December\u00a031, 2022 for risk management assets and liabilities measured at fair value on a recurring basis: Fair Value Measurements Using Carrying Amount Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value March 31, 2023 Risk-management instruments: Interest rate contracts designated as fair value hedges: Other noncurrent assets $ 2.7 $ \u2014 $ 2.7 $ \u2014 $ 2.7 Other current liabilities ( 9.9 ) \u2014 ( 9.9 ) \u2014 ( 9.9 ) Other noncurrent liabilities ( 91.8 ) \u2014 ( 91.8 ) \u2014 ( 91.8 ) Interest rate contracts designated as cash flow hedges: Other noncurrent assets 228.6 \u2014 228.6 \u2014 228.6 Cross-currency interest rate contracts designated as net investment hedges: Other receivables 55.6 \u2014 55.6 \u2014 55.6 Cross-currency interest rate contracts designated as cash flow hedges: Other noncurrent assets 58.2 \u2014 58.2 \u2014 58.2 Foreign exchange contracts designated as net investment hedges: Other receivables 0.9 \u2014 0.9 \u2014 0.9 Other current liabilities ( 13.1 ) \u2014 ( 13.1 ) \u2014 ( 13.1 ) Foreign exchange contracts not designated as hedging instruments: Other receivables 63.7 \u2014 63.7 \u2014 63.7 Other current liabilities ( 32.0 ) \u2014 ( 32.0 ) \u2014 ( 32.0 ) Contingent consideration liabilities: Other current liabilities ( 40.1 ) \u2014 \u2014 ( 40.1 ) ( 40.1 ) Other noncurrent liabilities ( 71.8 ) \u2014 \u2014 ( 71.8 ) ( 71.8 ) 23 Fair Value Measurements Using Carrying Amount Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value December 31, 2022 Risk-management instruments: Interest rate contracts designated as fair value hedges: Other noncurrent liabilities $ ( 134.3 ) $ \u2014 $ ( 134.3 ) $ \u2014 $ ( 134.3 ) Interest rate contracts designated as cash flow hedges: Other receivables 162.9 \u2014 162.9 \u2014 162.9 Other noncurrent assets 246.0 \u2014 246.0 \u2014 246.0 Cross-currency interest rate contracts designated as net investment hedges: Other receivables 67.6 \u2014 67.6 \u2014 67.6 Cross-currency interest rate contracts designated as cash flow hedges: Other noncurrent assets 53.1 \u2014 53.1 \u2014 53.1 Foreign exchange contracts designated as hedging instruments: Other current liabilities ( 38.3 ) \u2014 ( 38.3 ) \u2014 ( 38.3 ) Foreign exchange contracts not designated as hedging instruments: Other receivables 26.6 \u2014 26.6 \u2014 26.6 Other current liabilities ( 21.5 ) \u2014 ( 21.5 ) \u2014 ( 21.5 ) Contingent consideration liabilities: Other current liabilities ( 39.5 ) \u2014 \u2014 ( 39.5 ) ( 39.5 ) Other noncurrent liabilities ( 70.6 ) \u2014 \u2014 ( 70.6 ) ( 70.6 ) Risk-management instruments above are disclosed on a gross basis.",
      "score": 0.9952
    },
    {
      "sent": "18 Fair Value of Investments The following table summarizes certain fair value information at March\u00a031, 2023 and December\u00a031, 2022 for investment assets measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments: Fair Value Measurements Using Carrying Amount Cost (1) Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value March 31, 2023 Cash equivalents (2) $ 2,343.1 $ 2,343.1 $ 2,330.2 $ 12.9 $ \u2014 $ 2,343.1 Short-term investments: U.S.",
      "score": 0.9853
    },
    {
      "sent": "18 Fair Value of Investments The following table summarizes certain fair value information at March\u00a031, 2023 and December\u00a031, 2022 for investment assets measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments: Fair Value Measurements Using Carrying Amount Cost (1) Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value March 31, 2023 Cash equivalents (2) $ 2,343.1 $ 2,343.1 $ 2,330.2 $ 12.9 $ \u2014 $ 2,343.1 Short-term investments: U.S.",
      "score": 0.9853
    }
  ],
  "top_negative": [
    {
      "sent": "Gross Margin, Costs, and Expenses The following table summarizes our gross margin, costs, and expenses: Three Months Ended March 31, 2023 2022 Percent Change Gross margin $ 5,333.3 $ 5,737.9 (7) Gross margin as a percent of revenue 76.6 % 73.5 % Research and development $ 1,985.1 $ 1,610.1 23 Marketing, selling, and administrative 1,749.2 1,557.9 12 Acquired\ned to a purchase of a Priority Review Voucher.",
      "score": -0.9081
    },
    {
      "sent": "Trends Affecting Pharmaceutical Pricing, Reimbursement, and Access Reforms, including those that may stem from periods of economic downturn or uncertainty, or as a result of high inflation, emergence or escalation of, and responses to, war or unrest (including the Russia-Ukraine war), or government budgeting priorities, may continue to result in added pressure on pricing and reimbursement for our products.",
      "score": -0.8176
    },
    {
      "sent": "Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products.",
      "score": -0.7845
    }
  ],
  "forward_snippets": [
    "The following include some but not all of the factors that could cause actual results or events to differ materially from those anticipated: \u2022 the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals; \u2022 the impact and outcome of acquisitions and business development transactions and related costs; \u2022 the expiration of intellectual property protection for certain of our products and competition from generic and/or biosimilar products; \u2022 our ability to protect and enforce patents and other intellectual property; \u2022 changes in patent law or regulations related to data package exclusivity; \u2022 competitive developments affecting current products and our pipeline; \u2022 market uptake of recently launched products; \u2022 information technology system inadequacies, breaches, or operating failures; \u2022 unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in our information technology systems, networks, and facilities, or those of third parties with whom we share our data; \u2022 the impact of global macroeconomic conditions, trade disruptions, disputes, unrest, war, regional dependencies, or other costs, uncertainties and risks related to engaging in business globally; \u2022 unexpected safety or efficacy concerns associated with our products; \u2022 litigation, investigations, or other similar proceedings involving past, current, or future products or commercial activities as we are largely self-insured; \u2022 issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, or regulatory actions related to our facilities; \u2022 dependence on certain products for a significant percentage of our total revenue and an increasingly consolidated supply chain; \u2022 reliance on third-party relationships and outsourcing arrangements; \u2022 the impact of public health outbreaks, epidemics, or pandemics, such as the COVID-19 pandemic; \u2022 regulatory changes or other developments; \u2022 regulatory actions regarding operations and products; \u2022 continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and access to pharmaceuticals; \u2022 devaluations in foreign currency exchange rates or changes in interest rates and inflation; \u2022 changes in tax law, tax rates, or events that differ from our assumptions related to tax positions; \u2022 asset impairments and restructuring charges; \u2022 changes in accounting and reporting standards promulgated by the Financial Accounting Standards Board and the Securities and Exchange Commission (SEC); \u2022 regulatory compliance problems or government investigations; and \u2022 actual or perceived deviation from environmental-, social-, or governance-related requirements or expectations.",
    "Note\u00a03: Acquisitions and Divestitures We engage in various forms of business development activities to enhance our product pipeline, including acquisitions, collaborations, investments, and licensing arrangements.",
    "Under the terms of the agreement, we will receive $ 1.05 billion in cash upon successful closing of the transaction and an additional $ 305 million in cash upon the one year anniversary of closing.",
    "Under the terms of the agreement, we will receive $ 500 million in cash upon successful closing of the transaction and an additional $ 125 million in cash upon the one year anniversary of closing.",
    "Under the terms of the agreement, we will receive $ 1.05 billion in cash upon successful closing of the transaction and an additional $ 305 million in cash upon the one year anniversary of closing."
  ],
  "curated_text": "Symbol: LLY. Year: 2023. Period: Q3. ReportType: Q10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: 22 Fair Value of Risk-Management Instruments The following table summarizes certain fair value information at March\u00a031, 2023 and December\u00a031, 2022 for risk management assets and liabilities measured at fair value on a recurring basis: Fair Value Measurements Using Carrying Amount Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value March 31, 2023 Risk-management instruments: Interest rate contracts designated as fair value hedges: Other noncurrent assets $ 2.7 $ \u2014 $ 2.7 $ \u2014 $ 2.7 Other current liabilities ( 9.9 ) \u2014 ( 9.9 ) \u2014 ( 9.9 ) Other noncurrent liabilities ( 91.8 ) \u2014 ( 91.8 ) \u2014 ( 91.8 ) Interest rate contracts designated as cash flow hedges: Other noncurrent assets 228.6 \u2014 228.6 \u2014 228.6 Cross-currency interest rate contracts designated as net investment hedges: Other receivables 55.6 \u2014 55.6 \u2014 55.6 Cross-currency interest rate contracts designated as cash flow hedges: Other noncurrent assets 58.2 \u2014 58.2 \u2014 58.2 Foreign exchange contracts designated as net investment hedges: Other receivables 0.9 \u2014 0.9 \u2014 0.9 Other current liabilities ( 13.1 ) \u2014 ( 13.1 ) \u2014 ( 13.1 ) Foreign exchange contracts not designated as hedging instruments: Other receivables 63.7 \u2014 63.7 \u2014 63.7 Other current liabilities ( 32.0 ) \u2014 ( 32.0 ) \u2014 ( 32.0 ) Contingent consideration liabilities: Other current liabilities ( 40.1 ) \u2014 \u2014 ( 40.1 ) ( 40.1 ) Other noncurrent liabilities ( 71.8 ) \u2014 \u2014 ( 71.8 ) ( 71.8 ) 23 Fair Value Measurements Using Carrying Amount Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value December 31, 2022 Risk-management instruments: Interest rate contracts designated as fair value hedges: Other noncurrent liabilities $ ( 134.3 ) $ \u2014 $ ( 134.3 ) $ \u2014 $ ( 134.3 ) Interest rate contracts designated as cash flow hedges: Other receivables 162.9 \u2014 162.9 \u2014 162.9 Other noncurrent assets 246.0 \u2014 246.0 \u2014 246.0 Cross-currency interest rate contracts designated as net investment hedges: Other receivables 67.6 \u2014 67.6 \u2014 67.6 Cross-currency interest rate contracts designated as cash flow hedges: Other noncurrent assets 53.1 \u2014 53.1 \u2014 53.1 Foreign exchange contracts designated as hedging instruments: Other current liabilities ( 38.3 ) \u2014 ( 38.3 ) \u2014 ( 38.3 ) Foreign exchange contracts not designated as hedging instruments: Other receivables 26.6 \u2014 26.6 \u2014 26.6 Other current liabilities ( 21.5 ) \u2014 ( 21.5 ) \u2014 ( 21.5 ) Contingent consideration liabilities: Other current liabilities ( 39.5 ) \u2014 \u2014 ( 39.5 ) ( 39.5 ) Other noncurrent liabilities ( 70.6 ) \u2014 \u2014 ( 70.6 ) ( 70.6 ) Risk-management instruments above are disclosed on a gross basis. 18 Fair Value of Investments The following table summarizes certain fair value information at March\u00a031, 2023 and December\u00a031, 2022 for investment assets measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments: Fair Value Measurements Using Carrying Amount Cost (1) Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value March 31, 2023 Cash equivalents (2) $ 2,343.1 $ 2,343.1 $ 2,330.2 $ 12.9 $ \u2014 $ 2,343.1 Short-term investments: U.S. 18 Fair Value of Investments The following table summarizes certain fair value information at March\u00a031, 2023 and December\u00a031, 2022 for investment assets measured at fair value on a recurring basis, as well as the carrying amount and amortized cost of certain other investments: Fair Value Measurements Using Carrying Amount Cost (1) Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Fair Value March 31, 2023 Cash equivalents (2) $ 2,343.1 $ 2,343.1 $ 2,330.2 $ 12.9 $ \u2014 $ 2,343.1 Short-term investments: U.S. Top negative sentences: Gross Margin, Costs, and Expenses The following table summarizes our gross margin, costs, and expenses: Three Months Ended March 31, 2023 2022 Percent Change Gross margin $ 5,333.3 $ 5,737.9 (7) Gross margin as a percent of revenue 76.6 % 73.5 % Research and development $ 1,985.1 $ 1,610.1 23 Marketing, selling, and administrative 1,749.2 1,557.9 12 Acquired\ned to a purchase of a Priority Review Voucher. Trends Affecting Pharmaceutical Pricing, Reimbursement, and Access Reforms, including those that may stem from periods of economic downturn or uncertainty, or as a result of high inflation, emergence or escalation of, and responses to, war or unrest (including the Russia-Ukraine war), or government budgeting priorities, may continue to result in added pressure on pricing and reimbursement for our products. Due to a very restrictive market for litigation liability insurance, we are self-insured for litigation liability losses for all our currently and previously marketed products. Forward-looking snippets: The following include some but not all of the factors that could cause actual results or events to differ materially from those anticipated: \u2022 the significant costs and uncertainties in the pharmaceutical research and development process, including with respect to the timing and process of obtaining regulatory approvals; \u2022 the impact and outcome of acquisitions and business development transactions and related costs; \u2022 the expiration of intellectual property protection for certain of our products and competition from generic and/or biosimilar products; \u2022 our ability to protect and enforce patents and other intellectual property; \u2022 changes in patent law or regulations related to data package exclusivity; \u2022 competitive developments affecting current products and our pipeline; \u2022 market uptake of recently launched products; \u2022 information technology system inadequacies, breaches, or operating failures; \u2022 unauthorized access, disclosure, misappropriation, or compromise of confidential information or other data stored in our information technology systems, networks, and facilities, or those of third parties with whom we share our data; \u2022 the impact of global macroeconomic conditions, trade disruptions, disputes, unrest, war, regional dependencies, or other costs, uncertainties and risks related to engaging in business globally; \u2022 unexpected safety or efficacy concerns associated with our products; \u2022 litigation, investigations, or other similar proceedings involving past, current, or future products or commercial activities as we are largely self-insured; \u2022 issues with product supply and regulatory approvals stemming from manufacturing difficulties, disruptions, or shortages, including as a result of unpredictability and variability in demand, labor shortages, third-party performance, quality, or regulatory actions related to our facilities; \u2022 dependence on certain products for a significant percentage of our total revenue and an increasingly consolidated supply chain; \u2022 reliance on third-party relationships and outsourcing arrangements; \u2022 the impact of public health outbreaks, epidemics, or pandemics, such as the COVID-19 pandemic; \u2022 regulatory changes or other developments; \u2022 regulatory actions regarding operations and products; \u2022 continued pricing pressures and the impact of actions of governmental and private payers affecting pricing of, reimbursement for, and access to pharmaceuticals; \u2022 devaluations in foreign currency exchange rates or changes in interest rates and inflation; \u2022 changes in tax law, tax rates, or events that differ from our assumptions related to tax positions; \u2022 asset impairments and restructuring charges; \u2022 changes in accounting and reporting standards promulgated by the Financial Accounting Standards Board and the Securities and Exchange Commission (SEC); \u2022 regulatory compliance problems or government investigations; and \u2022 actual or perceived deviation from environmental-, social-, or governance-related requirements or expectations. Note\u00a03: Acquisitions and Divestitures We engage in various forms of business development activities to enhance our product pipeline, including acquisitions, collaborations, investments, and licensing arrangements. Under the terms of the agreement, we will receive $ 1.05 billion in cash upon successful closing of the transaction and an additional $ 305 million in cash upon the one year anniversary of closing. Under the terms of the agreement, we will receive $ 500 million in cash upon successful closing of the transaction and an additional $ 125 million in cash upon the one year anniversary of closing. Under the terms of the agreement, we will receive $ 1.05 billion in cash upon successful closing of the transaction and an additional $ 305 million in cash upon the one year anniversary of closing."
}